BiotechTube

3% Diquafosol tetrasodium

Pre-clinicalUNKNOWN
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetic Eye Problems

Conditions

Diabetic Eye Problems

Trial Timeline

Apr 1, 2023 → Nov 1, 2023

NCT ID
NCT05193331

About 3% Diquafosol tetrasodium

3% Diquafosol tetrasodium is a pre-clinical stage product being developed by Santen Pharmaceutical for Diabetic Eye Problems. The current trial status is unknown. This product is registered under clinical trial identifier NCT05193331. Target conditions include Diabetic Eye Problems.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT05193331Pre-clinicalUNKNOWN

Competing Products

20 competing products in Diabetic Eye Problems

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
44
CHF6467 activeComac MedicalPhase 1/2
33
Ruboxistaurin mesylateEli LillyPhase 3
77
KVD001 InjectionKalVista PharmaceuticalsPhase 2
47
KVD001 InjectionKalVista PharmaceuticalsPhase 1
28
Baricitinib + PlaceboEli LillyPhase 2
52
LY3857210 + PlaceboEli LillyPhase 2
52
UBX1325Unity BiotechnologyPhase 2
44
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
44
UBX1325Unity BiotechnologyPhase 1
25
CT-P42 + EyleaCelltrionPhase 3
77
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
85
Anplag(Sarpogrelate) + PlaceboYuhanApproved
85
CS-3150 + placeboDaiichi SankyoPhase 2
52
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
52
olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3
77
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
Beraprost sodiumAstellas PharmaPre-clinical
23

Other Products from Santen Pharmaceutical

Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77